相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer
L. Castagnoli et al.
ONCOGENE (2017)
Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host
Martina Di Modica et al.
DISEASE MARKERS (2017)
APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC)
Gunter Von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Lactate as a predictive marker for tumor recurrence in patients with head and neck squamous cell carcinoma (HNSCC) post radiation: a prospective study over 15 years
Sebastian Blatt et al.
CLINICAL ORAL INVESTIGATIONS (2016)
Lactate Contribution to the Tumor Microenvironment: Mechanisms, effects on immune Cells and Therapeutic Relevance
Susana Romero-Garcia et al.
FRONTIERS IN IMMUNOLOGY (2016)
Molecular magnetic resonance imaging in cancer
Mohammad Haris et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
limma powers differential expression analyses for RNA-sequencing and microarray studies
Matthew E. Ritchie et al.
NUCLEIC ACIDS RESEARCH (2015)
Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration
Tiziana Triulzi et al.
ONCOTARGET (2015)
Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy
M. E. Pisanu et al.
BRITISH JOURNAL OF CANCER (2014)
Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab
Lorenzo Castagnoli et al.
CANCER RESEARCH (2014)
Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study
Aleix Prat et al.
CLINICAL CANCER RESEARCH (2014)
Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies
K-K Shiu et al.
ONCOGENE (2014)
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2
Carla De Giovanni et al.
BREAST CANCER RESEARCH (2014)
Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study
M. Campiglio et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Optical Metabolic Imaging Identifies Glycolytic Levels, Subtypes, and Early-Treatment Response in Breast Cancer
Alex J. Walsh et al.
CANCER RESEARCH (2013)
Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31
Katherine L. Pogue-Geile et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Neoplastic and Stromal Cells Contribute to an Extracellular Matrix Gene Expression Profile Defining a Breast Cancer Subtype Likely to Progress
Tiziana Triulzi et al.
PLOS ONE (2013)
Imaging-Based Tumor Treatment Response Evaluation: Review of Conventional, New, and Emerging Concepts
Hee Kang et al.
KOREAN JOURNAL OF RADIOLOGY (2012)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Jose Baselga et al.
LANCET (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni et al.
LANCET ONCOLOGY (2012)
BREAST CANCER HER2-a good addiction
Lisa A. Carey
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Lactate: A Metabolic Key Player in Cancer
Franziska Hirschhaeuser et al.
CANCER RESEARCH (2011)
Activation of Phosphatidylcholine Cycle Enzymes in Human Epithelial Ovarian Cancer Cells
Egidio Iorio et al.
CANCER RESEARCH (2010)
Shed HER2 Extracellular Domain in HER2-Mediated Tumor Growth and in Trastuzumab Susceptibility
Gaia C. Ghedini et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2010)
HIF-1 alpha Modulates Energy Metabolism in Cancer Cells by Inducing Over-Expression of Specific Glycolytic Isoforms
Alvaro Marin-Hernandez et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2009)
An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance
Doyel Mitra et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth
Y. H. Zhao et al.
ONCOGENE (2009)
lumi:: a pipeline for processing Illumina microarray
Pan Du et al.
BIOINFORMATICS (2008)
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
HER-2:: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine
SM Pupa et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2005)
Hypoxia-inducible factor-1α and the glycolytic phenotype in tumors
IF Robey et al.
NEOPLASIA (2005)
HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis:: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression
E Laughner et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Tumor hypoxia:: Definitions and current clinical, biologic, and molecular aspects
M Höckel et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
分享论文
